Equilibra Bioscience

Equilibra Bioscience is a private, clinical-stage biotech advancing SR604, a novel anti-APC monoclonal antibody, as a potential treatment for hemophilia and other bleeding disorders. The company has initiated a Phase 1 clinical trial (NCT06349473) following U.S. FDA IND clearance and has secured Orphan Drug Designation for SR604 in hemophilia A and B. Its approach aims to rebalance the coagulation cascade by inhibiting the natural anticoagulant protein APC, offering a new mechanism of action for patients, including those with inhibitors.

Discovery and development of monoclonal antibodies targeting the activated Protein C (APC) pathway to rebalance the coagulation cascade in bleeding disorders.

The hemophilia market is competitive, dominated by factor replacements (e.g., from Takeda, Sanofi, Novo Nordisk) and the non-factor therapy emicizumab (Roche). Other novel mechanisms (e.g., fitusiran, concizumab) are also in development. SR604 must differentiate on efficacy, safety, or patient population to gain market share.